Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 28 2018 - 7:00AM
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders, today
announced that Herriot Tabuteau, MD, Axsome’s Chief Executive
Officer, will present a corporate overview at the 20th Annual
Rodman & Renshaw Global Investment Conference, sponsored by
H.C. Wainwright & Co., LLC., on September 5, 2018 at 2:10 PM
Eastern Time. The convention will be held at the St. Regis New York
Hotel in New York, NY.
A live webcast of the event can be viewed on the
company’s website at www.axsome.com.
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which
there are limited treatment options. Axsome’s product candidate
portfolio includes five clinical-stage candidates, AXS-02, AXS-05,
AXS-06, AXS-07, and AXS-09. AXS-05 is currently in a Phase 3 trial
in treatment resistant depression (TRD), a Phase 2/3 trial in
agitation associated with Alzheimer’s disease (AD), a Phase 2 trial
in Major Depressive Disorder (MDD), and a Phase 2 trial in smoking
cessation. AXS-02 is currently in a Phase 3 trial in knee
osteoarthritis (OA) associated with bone marrow lesions (BMLs) with
an additional Phase 3 trial planned in chronic low back pain (CLBP)
associated with Modic changes (MCs). AXS-07 is being developed for
the acute treatment of migraine. AXS-06 is being developed for the
treatment of osteoarthritis and rheumatoid arthritis and for the
reduction of the risk of NSAID-associated gastric ulcers. AXS-02,
AXS-05, AXS-06, AXS-07, and AXS-09 are investigational drug
products not approved by the FDA. For more information, please
visit the Company’s website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation and
completion of the trials, futility analyses and receipt of interim
results, which are not necessarily indicative of the final results
of our ongoing clinical trials; our ability to fund additional
clinical trials to continue the advancement of our product
candidates; the timing of and our ability to obtain and maintain
U.S. Food and Drug Administration or other regulatory authority
approval of, or other action with respect to, our product
candidates; the Company’s ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements;
the acceptance by the market of the Company’s product candidates,
if approved; and other factors, including general economic
conditions and regulatory developments, not within the Company’s
control. The factors discussed herein could cause actual results
and developments to be materially different from those expressed in
or implied by such statements. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstance.
Axsome Contact: Mark Jacobson
Senior Vice President, Operations Axsome Therapeutics, Inc. 25
Broadway, 9th Floor New York, NY 10004 Tel: 212-332-3243 Email:
mjacobson@axsome.com www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2023 to Apr 2024